Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells,

Read More

In what they describe as the most comprehensive analysis to date of the SARS-CoV-2 virus’s distribution and persistence in the body and brain, scientists at the U.S. National Institutes of Health said they found the pathogen is capable of replicating in human cells well beyond the respiratory tract. The results, released online Saturday in a

Read More

A number of antiviral immune defenses are compromised among people who develop severe COVID-19, a new single-cell RNA sequencing analysis has found. Some people infected with SARS-CoV-2 develop severe disease marked by acute respiratory failure and possibly sepsis and death. While studies have highlighted the possible role of systemic inflammatory responses in severe COVID-19, the

Read More

A German researcher thinks he knows what has caused some people to develop blood clots after receiving coronavirus vaccines. University of Greifswald hematologist Andreas Greinacher believes the reaction is linked to EDTA, a preservative found in the AstraZeneca vaccine. The AstraZeneca vaccine contains more than 1,000 proteins that have been derived from human proteins —

Read More

he game-changing Oxford vaccination could get the go-ahead “just after Christmas”, a leading expert has said . John Bell, Regius Professor of Medicine at Oxford University, stressed the data behind the jab is looking “better than ever”. The Medicines and Healthcare products Regulatory Agency is examining the vaccine developed by Oxford University and pharmaceutical giant AstraZeneca. With an announcement from the MHRA eagerly anticipated, Prof Bell told

Read More

Dr. Miguel Torres, of the Centro Nacional de Investigaciones Cardiovasculares (CNIC), leads a new project that will receive €8 million in funding over 5 years, €1,380,000 of which will be directly managed at the CNIC Research into new endogenous mechanisms of tissue regeneration is an innovative research avenue in cardiac regeneration. This is the central

Read More